Enterprise Value
-3.111B
Cash
3.449B
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.75%
Institutional Own.
64.05%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TJ202 (Felzartamab) (CD38 mAb) Details Multiple myeloma | BLA Submission | |
TJ101 (Eftansomatropin alfa) Details Pediatric growth hormone deficiency Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Lemzoparlimab Details High risk myelodysplastic syndromes | Phase 3 Update | |
TJ301 (Olamkicept) (gp130 IL-6 inhibitor) Details Ulcerative colitis, Autoimmune disease | Phase 3 Update | |
Felzartamab (MOR202) (CD38) Details IgA nephropathy | Phase 2 Data readout | |
TJ107 (Efineptakin alfa) (IL-7) Details Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma | Phase 2 Data readout | |
uliledlimab (TJD5) (TJ004309) (anti-CD73) (+ atezolizumab (TECENTRIQ®)) Details Cancer, Non-small cell lung carcinoma Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
MOR210 (TJ210) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Enoblituzumab (TJ271) + Pembrolizumab Details Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s | Failed Discontinued |